Creative Biolabs has announced a major upgrade to its mRNA technology platform, offering an integrated, end-to-end solution that spans design, delivery, and functional validation. The enhanced platform extends mRNA technology applications into induced pluripotent stem cell reprogramming, creating new opportunities for regenerative medicine and cell-based therapies.
The platform's in silico mRNA structural prediction capability enables detailed analysis of mRNA secondary structures and three-dimensional conformations using computational modeling, dynamic programming algorithms, and nearest-neighbor free-energy rules. This service supports multiple sequence alignment, conserved structure identification, primer design, and promoter analysis, allowing researchers to optimize mRNA constructs from the earliest stages of molecular design. This capability can function independently or support other mRNA development workflows.
At the delivery level, Creative Biolabs provides customized polymer development services through polyplex formation. By complexing cationic polymers such as polyethyleneimine and PDMAEMA with mRNA molecules, the platform generates nanoscale polyplexes with enhanced stability and high cellular uptake efficiency. The team adjusts polymer type, molecular weight, geometry, and N/P ratios to optimize carrier performance. These polyplex systems significantly improve mRNA stability in vivo and promote efficient intracellular release, serving as critical enablers for mRNA therapeutics including gene therapy and protein replacement applications.
The company has adapted its mRNA platform to iPSC reprogramming, offering a self-developed mRNA-based reprogramming service that is non-integrative and footprint-free. This approach allows sustained expression of reprogramming factors through repeated mRNA transfection, generating induced pluripotent stem cells with high efficiency while eliminating genomic integration risks associated with viral vectors. The method is both safe and highly scalable, supporting cell quantities ranging from millions to billions, making it suitable for various research and therapeutic applications.
Integrating these capabilities provides clients with a unified mRNA development pathway that accelerates projects from early construct optimization to functional demonstration. As mRNA technologies continue expanding across gene therapy, cancer vaccines, regenerative medicine, and cell therapy, this enhanced platform positions Creative Biolabs to support pharmaceutical, biotechnology, and academic programs worldwide. The company's comprehensive approach addresses critical challenges in mRNA stability, delivery efficiency, and safety concerns in stem cell generation, potentially accelerating the development of next-generation therapeutics and regenerative medicine applications.
